精神病临床高危状态或近期起病抑郁患者功能结局的多模态多中心机器学习预测模型
该多中心自然随访研究纳入116例精神病临床高危(CHR)患者和120例近期起病抑郁(ROD)患者,随访约18个月,采用临床、影像及联合机器学习预测1年社会功能结局。联合模型平衡准确率CHR为82.7%、ROD为70.3%,优于专家预测,并可提升不确定病例的预后确定性。
要点
- 联合机器学习预测1年社会功能结局的平衡准确率CHR为82.7%、ROD为70.3%。
- 基线功能较低是跨诊断预测因子,影像特征在两组中预测价值不同。
- 机器学习优于专家预测,加入影像可提升不确定病例的预后确定性。
核心结论
- 临床、影像及联合机器学习可预测CHR或ROD患者1年社会功能结局,联合模型表现最佳。
- 机器学习预测优于专家判断,加入神经影像可提高不确定病例的预后确定性。
研究设计与样本
- 多中心自然随访研究,在5个欧洲国家7个早期识别服务中心招募受试者。
- 纳入116例CHR患者和120例ROD患者,随访平均329天(SD 142天)。
- 采用临床、结构神经影像及联合机器学习建模,并评估地理、跨诊断和预后泛化性。
主要发现
- 临床基线数据预测1年社会功能结局的平衡准确率CHR为76.9%、ROD为66.2%。
- 结构神经影像模型平衡准确率CHR为76.2%、ROD为65.0%;联合模型CHR为82.7%、ROD为70.3%。
- 基线功能较低是跨诊断预测因子;CHR组内侧前额及颞顶枕灰质体积减少、小脑及背外侧前额灰质体积增加有预测价值。
- ROD组内侧颞叶灰质体积减少及前额-岛周灰质体积增加有预测价值。
- CHR组不良预后与随访时精神病性、抑郁和焦虑障碍风险增加相关,ROD组未见此关联。
关键数值与推荐
- CHR组联合模型平衡准确率82.7%,ROD组70.3%。
- 临床机器学习加入神经影像机器学习后,CHR不确定病例预后确定性提高1.9倍,ROD提高10.5倍。
临床怎么用
- 可基于临床基线数据构建预测模型,对CHR和ROD患者进行社会功能结局风险分层。
- 在临床预测不确定时,可结合结构神经影像机器学习提高预后判断确定性。
- 基线功能较低应作为跨诊断重点评估指标,用于识别功能不良高危个体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Social and occupational impairments contribute to the burden of psychosis and depression. There is a need for risk stratification tools to inform personalized functional-disability preventive strategies for individuals in at-risk and early phases of these illnesses. OBJECTIVE: To determine whether predictors associated with social and role functioning can be identified in patients in clinical high-risk (CHR) states for psychosis or with recent-onset depression (ROD) using clinical, imaging-based, and combined machine learning; assess the geographic, transdiagnostic, and prognostic generalizability of machine learning and compare it with human prognostication; and explore sequential prognosis encompassing clinical and combined machine learning. DESIGN, SETTING, AND PARTICIPANTS: This multisite naturalistic study followed up patients in CHR states, with ROD, and with recent-onset psychosis, and healthy control participants for 18 months in 7 academic early-recognition services in 5 European countries. Participants were recruited between February 2014 and May 2016, and data were analyzed from April 2017 to January 2018. AIN OUTCOMES AND MEASURES: Performance and generalizability of prognostic models. RESULTS: A total of 116 individuals in CHR states (mean [SD] age, 24.0 [5.1] years; 58 [50.0%] female) and 120 patients with ROD (mean [SD] age, 26.1 [6.1] years; 65 [54.2%] female) were followed up for a mean (SD) of 329 (142) days. Machine learning predicted the 1-year social-functioning outcomes with a balanced accuracy of 76.9% of patients in CHR states and 66.2% of patients with ROD using clinical baseline data. Balanced accuracy in models using structural neuroimaging was 76.2% in patients in CHR states and 65.0% in patients with ROD, and in combined models, it was 82.7% for CHR states and 70.3% for ROD. Lower functioning before study entry was a transdiagnostic predictor. Medial prefrontal and temporo-parieto-occipital gray matter volume (GMV) reductions and cerebellar and dorsolateral prefrontal GMV increments had predictive value in the CHR group; reduced mediotemporal and increased prefrontal-perisylvian GMV had predictive value in patients with ROD. Poor prognoses were associated with increased risk of psychotic, depressive, and anxiety disorders at follow-up in patients in the CHR state but not ones with ROD. Machine learning outperformed expert prognostication. Adding neuroimaging machine learning to clinical machine learning provided a 1.9-fold increase of prognostic certainty in uncertain cases of patients in CHR states, and a 10.5-fold increase of prognostic certainty for patients with ROD. CONCLUSIONS AND RELEVANCE: Precision medicine tools could augment effective therapeutic strategies aiming at the prevention of social functioning impairments in patients with CHR states or with ROD.
引用
- Koutsouleris N, Kambeitz-Ilankovic L, Ruhrmann S, et al. Prediction Models of Functional Outcomes for Individuals in the Clinical High-Risk State for Psychosis or With Recent-Onset Depression: A Multimodal, Multisite Machine Learning Analysis. JAMA Psychiatry. 2018. PMID: 30267047. doi:10.1001/jamapsychiatry.2018.2165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。